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Abstract
Scientific and pharmaceutical advancements have revolutionized medicine. Many once- debilitating or fatal diseases can now be
managed with medication. However, the search for a cure for the inevitable aging diseased state remained futile until recently.
Rapamycin has been studied for its possible longevity effects, providing promising results for the development of anti-aging therapies.
This paper evaluates the benefits and risks of rapamycin use. While rapamycin cannot be supported as a safe anti-aging drug,
rapamycin studies have elucidated parts of the aging pathway, providing a breakthrough for anti-aging research.
Abbreviations
FKBP - FK506 Binding Protein
AKT – protein kinase B
Introduction
Hutchinson-Gilford Progeria Syndrome (progeria) is a
rare genetic disease caused by a mutation on the LMNA
gene which encodes for the Lamin-A protein. This causes
a modified form of Lamin-A, known as progerin, which has
an internal deletion of fifty amino acids (Graziotto et al.
2012). Wild-type Lamin A is the scaffolding of a cell, which
holds the nucleus together. Researchers believe the variant
Lamin-A leads to an unstable nucleus that causes the symptoms of progeria (The Progeria Research Foundation).
Children with progeria show early signs of aging, which
include loss of body fat and hair, growth failure, stiffness of
joints, aged looking skin, hip dislocation, cardiovascular disease, stroke, and generalized atherosclerosis. The lifespan
of children with HGPS is fourteen years, with the common
cause of death atherosclerosis (The Progeria Research
Foundation).
The Progeria Research Foundation is currently conducting a clinical research trial to test a possible cure for
Progeria.The trial is testing the combined use of Lonafarnib
and Everolimus on HGPS patients. Lonafarnib is a farnesyltransferase inhibitor. By inhibiting the attachment of a
farsenyl group to progerin, the progerin is unable to inhibit the cell function (The Progeria Research Foundation).
Everolimus, a derivative of rapamycin, promotes the autophagy of the progerin (Graziotto et al. 2012).
Increased levels of progerin have been found in the
skin and arteries of normal, aged individuals (McClintock
et al. 2007, Olive et al. 2010). The correlation between
increased progerin and the physiology of aging is seen in
the rapid aging of HGPS patients with high levels of progerin and the decrease in age-associated symptoms upon
autophagic degeneration of progerin. Thus, the correlation between HGPS and normal aging suggest rapamycin
as a possible drug to promote longevity in the general
population (Graziotto et al. 2012).
In 2009, a study showing that rapamycin extends the
lifespan of mice was published. This was the first study to
realize the anti-aging properties of rapamycin on mammals (Harrison et al. 2009). Since then, rapamycin has
been explored as a possible anti-aging drug for humans.

Method
Articles sourced in this paper were obtained by searching
Touro’s database and Google Scholar. Some articles were
referenced in review articles and the original articles
were retrieved. Additionally, data was obtained from the
Progeria Research Foundation and the lecture of Michael
Hall who discovered and studies TOR.
Discussion
The Mechanism of Rapamycin
Rapamycin is a macrocyclic lactone secreted by the bacterium streptomyces hygroscopicus which was discovered
on the Easter Island (Tee 2018). Is was originally intended
for use as an antifungal. However, its immunosuppressive
and anti- proliferative properties rendered it unsuitable
as a safe antifungal treatment. Instead, these properties of
rapamycin led to its development for other purposes, and
rapamycin along with its derivatives are FDA approved
for use as immunosuppressants and an anticancer agent
(Lamming 2016).
Rapamycin combines with FKBP to inhibit the activity of
the mechanistic target of rapamycin (mTOR), which is part
of the phosphatidylinositol 3-kinase-related kinases family
(Hall 2016). The mTOR protein forms two protein kinase
complexes - mTORC1 and mTORC2, both balancing cell
growth and metabolism with degradation. The mTOR
pathways responds to favorable growth conditions, such
as adequate nutrition, resources, and growth factors by
stimulating anabolic processes (Kennedy, Lamming 2016,
Laplante, Sabatini 2009). Conversely, stressful conditions
in the cell inhibit the mTOR pathway, thereby inducing
catabolic processes (Laplante, Sabatini 2009).
The two mTOR complexes have some shared components. They both contain the mTOR core, the regulatory
protein Deptor, and mLST8/GβL to ensure complex assembly and stability (Kennedy, Lamming 2016).
In mTORC1, the mTOR protein kinase interacts
with the scaffold protein Raptor, and the AKT substrate
PRAS40 (Kennedy, Lamming 2016). As shown in in Figure
1, MTORC1 controls many processes, including protein
synthesis, lipid synthesis, autophagy, mitochondrial metabolism, and biogenesis (Laplante, Sabatini 2009). Many of
the functions of mTORC1 are inhibited by acute exposure
to rapamycin which causes a decrease in biosynthesis and
an increase in biodegradation (Tee 2018, Hall 2017).
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survival, metabolism, proliferation, and
cytoskeleton organization (Laplante,
Sabatini 2009). The pathways involving
mTORC2 are outlined in Figure 2.
What Anti-Aging Effects does
Rapamycin have on the Body?
MTORC1 controls many processes linked
to aging. Therefore, the inhibition of these
processes by rapamycin contribute to
the drug’s anti-aging effects (Johnson et
al. 2013). The suggested mechanisms of
reduced aging by mTORC1 inhibition are
discussed in this section.
MTORC1 inhibition promotes autophagy,
which is the recycling of amino acids and
degradation of damaged macromolecules
Figure 1. Diagram of the pathways involving mTORC1 (Kennedy, Lamming 2016)
and organelles. Autophagy in the cells
declines with age, and it is proposed that
the accumulation of damaged particles
contribute to cellular dysfunction of aged
individuals (Cuervo 2008). MTROC1 inhibition promotes autophagic mediated
longevity, as supported by studies on yeast
and invertebrate (Johnson et al 2013).
Regulation of mRNA translation is another process that may contribute to the
anti-aging benefits of rapamycin. Under
favorable growth conditions, mTROC1
promotes mRNA translation and protein
synthesis. Inhibition of mTORC1 reduces
translation, and studies on yeast, nematodes, fruit flies, and mice provide evidence
Figure 2. Diagram of the pathways involving mTORC2 (Kennedy, Lamming 2016)
that regulation of mRNA translation inMTORC2 contains the scaffold protein Rictor, the
creases lifespan (Kaeberlein, Kennedy 2011). A main reaprotein subunits mSIN1 and Protor-1/2 (Laplante 2009).
son for the increased lifespan accompanying global mRNA
Prolonged rapamycin use inhibits mTORC2 by binding to
translation reduction is the differential protein translation
free mTOR and preventing it from forming the mTORC2
of specific mRNA. Molecular evidence is seen in yeast;
complex (Johnson et al. 2013, Sarbassov et al. 2006, Tee
when mTORC1 is inhibited Gcn4 is preferentially trans2018). MTORC2 is stimulated by IGF-1, insulin, and leptin
lated and increased translation of Gcn4 increases lifespan.
(Kennedy, Lamming 2016). MTORC2 regulates mTORC1
Similar mechanisms are seen in studies of nematodes and
via the phosphorylation of AKT. AKT phosphorylates
fruit flies (Johnson et al 2013).
TSC2, which is part of the TSC complex. TSC2 promotes
Another function possibly contributing to the anti-agthe conversion of Rheb-GTP, which activates mTORC1
ing benefit of rapamycin is reduced inflammation through
to Rheb- GDP. Therefore, the phosphorylation of TSC2
mTORC1 inhibition. Hyperactivation of mTORC1 causes
inhibits this conversion process, allowing the Rhebinflammation which is present in many age-related disGTP complex to remain in its active form and activate
eases such as kidney disease, vascular inflammation after
mTORC1 (Manning, Toker 2017). AKT also phosphoryangioplasty, atherosclerotic plaques, and lung infection.
lates PRAS40It, which is an inhibitor of mTORC1 in its
Therefore, rapamycin use reduces inflammation associated
unphosphorylated form (Sancak et al., 2007). The other
with these diseases. (Johnson et al 2013).
regulatory functions of mTORC2 include regulating cell
Additionally, studies on yeast link mTORC1 inhibition to
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the activation of a stress response pathway. The increased
stress resistance promotes lifespan extension. Also, regulation of mitochondrial function and enhanced stem cell
function seem to contribute to the longevity effects of
rapamycin (Johnson et al 2013).
Rapamycin Studies on Mammals
The 2009 study conducted by Harrison et al. on 1,901 mice
provides evidence for the longevity effects of rapamycin on
mammals. In comparison to the control group, rapamycinfed female mice had a 13% lifespan extension, and male
mice had a 9% lifespan extension. The average age of the
mice was 600 days, which is the equivalence of 60 years in
humans. Thus, the study demonstrates rapamycin’s effectiveness when started late in the lifespan.
In 2019 Sills et al. studied the safety of rapamycin on 23
middle-aged marmosets who were fed rapamycin for nine
months. The marmoset showed no significant side effects
and only minor effects on hematological markers. Since
marmosets are biologically similar to humans, the study
suggest similar outcomes would occur in humans.
Rapamycin Side Effects in Humans
Although rapamycin has been found to increase the lifespan of flies, mice, and marmosets, few studies have tested
its anti-aging effect on humans (Graziotto et al. 2012). This
section will review negative side effects of rapamycin treatment and the evidence to support the drug as an anti-aging
therapy for humans.
Many studies on rapamycin have been conducted on immunocompromised patients. Side effects of renal and heart
transplant patients taking rapamycin for its immunosuppressive property include delayed wound healing, interstitial pneumonitis, anemia, high cholesterol and triglyceride
levels, infection, edema, and gastrointestinal symptoms.
(Baur et al. 2011, Ekberg et al. 2010, Graziotto et al. 2012).
Long term side effects of rapamycin include glucose intolerance, decreased insulin sensitivity, and increased risk of
new onset diabetes (Johnston et al. 2008, Lamming 2016).
While these reported side effects may seem to outweigh
the potential benefits of rapamycin, it is important to consider that the adverse effects may be influenced by the
patients’ underlying condition or drug interactions (Kraig
et al. 2018).
A small-scale study found that short term everolimus
treatment boosted the immune response of normal, elderly
individuals to the flu vaccine. This suggests that rapamycin
improves immunosenescence, one characteristic of aging.
Since rapamycin is also known for its immunosuppressive
properties, its effects on the immune system seem to be dependent on disease, age, and/or antigen (Mannick et al. 2014).

Another small-scale study of a similar population found
rapamycin use safe for elderly individuals with stabilized
medical conditions. This population did not show a significant change in plasma glucose, insulin, and insulin sensitivity,
which contrasts with the increased risk of diabetes seen
with transplant patients.Additionally, there was no significant
elevation in triglyceride levels, which was also a concerning
side effect seen in previous studies. The side-effects reported in the study group were limited to a facial rash and GI
symptoms. However, the study did not reveal any change
in cognitive functioning, physical performance, or immune
parameters.While these results do not support the anti-aging benefits of rapamycin, the limited side-effects on normal
individuals support the safety of rapamycin use for further
clinical testing (Kraig et al. 2018).
Despite the promising results of life extension seen in
mammals, only a limited number of clinical trials with small
sample sizes were conducted on humans. Therefore, rapamycin must undergo further studies to determine its efficacy.
Conclusion/Further Research
The substantial side-effects associated with rapamycin
use in transplant patients makes it difficult for it to be
approved as a preventative aging treatment. However,
the discovery of life extension by inhibiting mTOR provides a basis for the search of other anti-aging treatments
that work by a similar mechanism. One suggestion is
MTORC1 specific- inhibition, which is sufficient to extend
lifespan and may have reduced side effects. Studies have
demonstrated the importance of mTORC2 in human
physiology and metabolism (Lamming et al. 2016). For
example, mTORC2 plays an important role in B-Cells,
T-cell and macrophages (Byles et al. 2013, Festuccia et al.
2014). Additionally, prolonged ex-vivo exposure to rapamycin inhibits lipogenesis in rat hepatocyte which can be
attributed to the disruption of mTORC2 (Brown et al.
2007, Kennedy, Lamming 2016).
Kennedy and Lamming found that while chronic exposure to FKBP12-rapamycin complex inhibits mTORC2,
chronic exposure to the rapamycin-FKBP51 complex
does not inhibit mTORC2. The binding affinity of rapamycin with FBPK51 has an inverse relationship with the
inhibition of mTROC2. Therefore, a rapamycin analog
with a strong affinity for FKPB51 should be studied as a
mTORC1 specific inhibitor (2016).
Another possibility, which is not well-studied, is to harness the benefits of rapamycin by eating a low-protein
diet. Amino acids are one of the stimuli for mTORC1,
but not mTROC2 (Lamming 2016). Studies show leucine
consumption affects mTORC1 activity in humans, and a
short-term protein-free diet reduces mTORC1 signaling
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(Moberg et al. 2014, Harputlugil et al. 2014). The branchchain amino acids - leucin, isoleucine and valine – enhance
the mTORC1 activity in skeletal muscle, liver, pancreas
and adipose tissue in rodents. Therefore, a diet with limited proteins or specific amino acids may provide a more
natural approach to reduce aging (Lamming 2016).
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